ClinicalTrials.gg
RecruitingNCT06341699MiSterOUpdated May 13, 2025

Study of the Steroid Hormone Milieu in Obese Patients

An observational study in Obesity, Morbid, sponsored by Istituto Auxologico Italiano. Recruiting at 1 site in Italy. Open to male participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-13.

Sponsored by Istituto Auxologico Italiano · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Ecologic or community
Time perspective
Cross-sectional
Enrollment
180
Ages
18 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Obesity, Morbid with a site in Italy — 11 open to participants now, 12 under way, none of them phase 3. Obesity, Morbid · Italy.

Planned enrollment
15th of 29
180 · median 180
Started
2023
with 3 others
Observational
29 of 54
3 open now
Primary completion
2026-06
later than 3 of 11 live
Registered
50th of 54
by date
Lead sponsor
5 of 54
Istituto Auxologico Italiano

Among the 54 studies in Obesity, Morbid with a site in Italy, this one is the 15th largest by planned enrollment of the 29 observational ones that give a count, is one of 4 that started in 2023, is one of 29 observational ones, reaches primary completion later than 3 of the 11 other live ones, and was the 50th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

11 of the 54 studies in Obesity, Morbid with a site in Italy are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Obesity, Morbid with a site in Italy, or all of them as a file.
02

Study summary

The aim of this observational study is to evaluate the actual secretion of cortisol and testosterone in obese male subjects, together with the receptor sensitivity to these hormones in order to understand whether the hormonal milieu deriving from these parameters is associated with alterations in bone metabolism, lipoprotein concentration and function, and/or the severity and complications of obesity.

It will be also investigated if this hormonal milieu is a predictive factor for cardiovascular disease in obese patients.

Eligible subjects are male patients (age 18-80 years) with severe obesity and no other known causes of hypercortisolism or hypogonadism.

Questionnaires for the evaluation of mood and symptoms will be collected upon enrollment, patient's anamnestic and clinical data relating to disease complications, BMI, previous blood tests, cortisol suppression with dexamethasone 1 mg will be collected, and blood sample will be sent to and analyzed at a centralized laboratory for the study of Steroid hormones, bone metabolism, lipoprotein function, genetics and receptor analysis.

03

Conditions studied

  • Obesity, Morbid

Keywords

  • hypercortisolism
  • hypogonadism
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients affected with severe obesity

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • morbid obesity

Exclusion criteria

Exclusion Criteria:

  • patients suffering from severe systemic pathologies, fever, chronic inflammatory states known to cause PCR >10 mg/dL
  • use of at the time of enrollment
  • the patient's poor understanding of spoken and written Italian
  • patients suffering from primary pathologies of the testicle, known at enrollment
  • patients suffering from hypothalamic-pituitary or adrenal pathologies already known at the time of enrollment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Ecologic or community
Time perspective
Cross-sectional
Enrollment
180 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Association of androgen milieu with the severity of obesity

    Evaluate the association of hypogonadism and/or androgen receptor polymorphisms that reduce sensitivity to androgens with: patients' BMI; comorbidities of obesity, and bone metabolism

    Time frame: 2024

  2. Association of cortisol milieu with the severity of obesity

    Evaluate the association of hypercortisolism and/or glucocorticoid receptor polymorphisms that increase sensitivity to cortisol with: patients' BMI; comorbidities of obesity, and bone metabolism

    Time frame: 2024

  3. Algorithm fo CV risk in obesity

    Use of artificial intelligence methods to hypothesize an algorithm including steroid milieu that can identify obese patients at greater cardiovascular risk

    Time frame: 2024

Secondary outcomes

  1. Prevalence of hypogonadism in morbid obesity

    To evaluate the prevalence of hypogonadism in patients with severe obesity using EMAS criteria

    Time frame: 2024

  2. Prevalence of patients with morbid obesity unresponsive to overnight suppression test

    To evaluate the prevalence of patients with severe obesity positive to Nugent testing

    Time frame: 2024

  3. Enrichment in rare HH variants in obese patients with central hypogonadism

    Compare the enrichment in rare variants for HH-associated genes in obese patients with hypogonadotropic hypogonadism, compared to the general population

    Time frame: 2025

  4. Enrichment in rare variants associated with hypercortisolism in obese patients unresponsive to Nugent testing

    Compare the enrichment in rare variants in genes associated with hypercortisolism in obese patients unresponsive to Nugent testing, compared to the general population

    Time frame: 2025

07

Study locations

1 of 1 sites recruiting
  • Istituto Auxlogico Italiano, Hospital San Giuseppe, Piancavallo
    Oggebbio, Verbania 28824, Italy
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2023 (actual). Primary completion is estimated for Jun 2026, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2024
First posted
Apr 2, 2024
StartActual
May 16, 2023
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jun 30, 2026
Last update
May 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06341699
Collaborators
Ministry of Health, Italy
Responsible party
Sponsor
First posted
Apr 2, 2024
Start date
May 16, 2023
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
May 13, 2025

Study contacts

Biagio Cangiano, MD
Contact
b.cangiano@auxologico.it
3343177491

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion